Table 3 Summary of findings 2: biological treatments compared to placebo for Psoriatic Arthritis—PsARC
Summary of findings | ||||||
|---|---|---|---|---|---|---|
Biological treatment effects to PsARC outcome (6-month follow-up) in the treatment of Psoriatic Arthritis patients | ||||||
Population: Psoriatic Arthritis patients Intervention: Biological treatments (Adalimumab, Etanercept, Infliximab, Golimumab, Certolizumab pegol) and synthetic target-specific drugs (Tofacitinib) Comparator (reference): Placebo |
| |||||
Biological treatments | Anticipated absolute effect* (95% CI) | Relative effect (95% CI) | No of participants (studies) | Certainty of evidence (GRADE) | Ranking | |
Without intervention | With intervention | |||||
Etanercept | 23 per 100 | 76 per 100 (46–100) | RR 3.27 (1.98–5.42) | 265 (2 RCTs) | ⨁⨁◯◯ Low | 1º - P-score = 0.91 |
Infliximab | 28 per 100 | 75 per 100 (47–100) | RR 2.64 (1.65–4.22) | 304 (2 RCTs) | ⨁⨁◯◯ Low | 2º - P-score = 0.78 |
Certolizumab pegol | 33 per 100 | 78 per 100 (44–100) | RR 2.35 (1.33–4.14) | 409 (1 RCT) | ⨁⨁◯◯ Low | 3º - P-score = 0.68 |
Adalimumab | 31 per 100 | 61 per 100 (44–84) | RR 1.95 (1.41–2.69) | 652 (4 RCTs) | ⨁⨁⨁◯ Moderate | 4º - P-score = 0.53 |
Tofacitinib | 36 per 100 | 58 per 100 (39–86) | RR 1.62 (1.09–2.40) | 474 (2 RCTs) | ⨁◯◯◯ Very low | 5º - P-score = 0.37 |
Golimumab | 73 per 100 | 85 per 100 (47–100) | RR 1.17 (0.64–2.13) | 42 (1 RCT) | ⨁◯◯◯ Very low | 6º - P-score = 0.17 |
Placebo | – | – | Reference comparator | – | – | – |
